RU2005126412A - Сор1 для лечения воспалительных заболеваний кишечника - Google Patents
Сор1 для лечения воспалительных заболеваний кишечника Download PDFInfo
- Publication number
- RU2005126412A RU2005126412A RU2005126412/15A RU2005126412A RU2005126412A RU 2005126412 A RU2005126412 A RU 2005126412A RU 2005126412/15 A RU2005126412/15 A RU 2005126412/15A RU 2005126412 A RU2005126412 A RU 2005126412A RU 2005126412 A RU2005126412 A RU 2005126412A
- Authority
- RU
- Russia
- Prior art keywords
- copolymer
- pharmaceutical composition
- active agent
- inflammatory bowel
- bowel disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Фармацевтическая композиция для лечения воспалительного заболевания кишечника, содержащая активный агент, выбранный из группы, состоящей из сополимера 1, сополимер 1-родственного полипептида и сополимер 1-родственного пептида, и фармацевтически приемлемый носитель.
2. Фармацевтическая композиция по п.1, где указанным воспалительным заболеванием кишечника является болезнь Крона.
3. Фармацевтическая композиция по п.1, где указанным воспалительным заболеванием кишечника является язвенный колит.
4. Фармацевтическая композиция по любому из пп.1-3, где указанным активным агентом является сополимер 1.
5. Фармацевтическая композиция по любому из пп.1-3, где указанным активным агентом является сополимер 1-родственный пептид или сополимер 1-родственный полипептид.
6. Фармацевтическая композиция по любому из пп.1-3 для орального введения.
7. Фармацевтическая композиция по любому из пп.1-3 для введения внутримышечно, подкожно, интрадермально или путем ингаляции.
8. Применение активного агента, выбранного из группы, состоящей из сополимера 1, сополимер 1-родственного полипептида и сополимер 1-родственного пептида, для лечения воспалительного заболевания кишечника.
9. Применение по п.8, где указанным воспалительным заболеванием кишечника является болезнь Крона.
10. Применение по п.8, в котором указанным воспалительным заболеванием кишечника является язвенный колит.
11. Применение по любому из пп.8-10, в котором указанным активным агентом является сополимер 1.
12. Применение по любому из пп.8-10, в котором указанным активным агентом является сополимер 1-родственный пептид или сополимер 1-родственный полипептид.
13. Применение по любому из пп.8-10 путем орального введения.
14. Применение по любому из пп.8-10 путем введения внутримышечно, подкожно, интрадермально или путем ингаляции.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44113603P | 2003-01-21 | 2003-01-21 | |
US60/441,136 | 2003-01-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2005126412A true RU2005126412A (ru) | 2006-01-27 |
RU2339397C2 RU2339397C2 (ru) | 2008-11-27 |
Family
ID=32771907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005126412/15A RU2339397C2 (ru) | 2003-01-21 | 2004-01-20 | Сор1 для лечения воспалительных заболеваний кишечника |
Country Status (14)
Country | Link |
---|---|
US (1) | US8008258B2 (ru) |
EP (1) | EP1592384B1 (ru) |
AU (1) | AU2004206120B2 (ru) |
CA (1) | CA2513567C (ru) |
DK (1) | DK1592384T3 (ru) |
ES (1) | ES2397836T3 (ru) |
MX (1) | MXPA05007711A (ru) |
NO (1) | NO333579B1 (ru) |
NZ (1) | NZ569331A (ru) |
PT (1) | PT1592384E (ru) |
RU (1) | RU2339397C2 (ru) |
SI (1) | SI1592384T1 (ru) |
WO (1) | WO2004064717A2 (ru) |
ZA (1) | ZA200505733B (ru) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
NZ533327A (en) * | 2001-12-04 | 2006-11-30 | Teva Pharma | Processes for the measurement of the potency of glatiramer acetate |
US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
NZ551236A (en) * | 2004-05-07 | 2010-11-26 | Peptimmune Inc | Methods of treating disease with random copolymers |
US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
WO2006029411A2 (en) * | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
JP2008528589A (ja) * | 2005-02-02 | 2008-07-31 | テバ ファーマシューティカル インダストリーズ リミティド | 水素化分解を用いてポリペプチド混合物を作成する方法 |
US20100167983A1 (en) * | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
EP2318012A4 (en) * | 2008-07-25 | 2011-08-24 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING AUTOIMMUNE DISEASES |
NZ598661A (en) | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
CN105797145A (zh) * | 2010-07-26 | 2016-07-27 | Qu生物制药公司 | 免疫原性抗炎组合物 |
MX347871B (es) | 2010-10-11 | 2017-05-16 | Teva Pharmaceutical Ind Ltd * | Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero. |
ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
WO2013009885A2 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Evaluation of copolymer diethylamide |
US8575198B1 (en) | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
TW201326399A (zh) | 2011-10-10 | 2013-07-01 | Teva Pharma | 用於預測對格拉替雷(glatiramer)醋酸鹽之臨床反應之單核苷酸多型性之判定 |
US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
US10251946B2 (en) | 2014-05-02 | 2019-04-09 | Qu Biologics Inc. | Anti-microbial immunomodulation |
US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
EP3478300B1 (en) | 2016-06-30 | 2022-08-24 | Stem Cell Medicine Ltd. | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells |
US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
IL269893B2 (en) | 2017-05-15 | 2023-10-01 | Stem Cell Medicine Ltd | Treatment of multiple sclerosis using stem cells derived from adipose tissue |
EP3624815A4 (en) | 2017-05-15 | 2021-01-20 | Stem Cell Medicine Ltd. | TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
US5858964A (en) * | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
WO2000005250A1 (en) * | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
AU766498B2 (en) * | 1998-07-23 | 2003-10-16 | President And Fellows Of Harvard College, The | Synthetic peptides and methods of use for autoimmune disease therapies |
DE09004306T1 (de) | 1998-09-25 | 2010-12-09 | Yeda Research & Development Co., Ltd., Weizmann Institute of Science | Mit Copolymer 1 verwandte Polypeptide zur Verwendung als Molekulargewichtsmarker und zur therapeutischen Verwendung |
AU6281599A (en) * | 1998-10-02 | 2000-04-26 | Yeda Research And Development Co. Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
CA2355400A1 (en) * | 1998-11-12 | 2000-05-18 | Yeda Research And Development Co., Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
AU3108001A (en) * | 2000-01-20 | 2001-12-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing a th2 immune response |
AU3846901A (en) * | 2000-02-18 | 2001-08-27 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formualtions of copolymer 1 |
AU2003204344A1 (en) * | 2002-05-23 | 2003-12-11 | Milder, Dan George | Compositions and methods for the treatment of autoimmune diseases and neurological disorders |
WO2006029411A2 (en) * | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
-
2004
- 2004-01-20 EP EP04703462A patent/EP1592384B1/en not_active Expired - Lifetime
- 2004-01-20 ZA ZA200505733A patent/ZA200505733B/en unknown
- 2004-01-20 MX MXPA05007711A patent/MXPA05007711A/es active IP Right Grant
- 2004-01-20 ES ES04703462T patent/ES2397836T3/es not_active Expired - Lifetime
- 2004-01-20 RU RU2005126412/15A patent/RU2339397C2/ru not_active IP Right Cessation
- 2004-01-20 PT PT47034624T patent/PT1592384E/pt unknown
- 2004-01-20 AU AU2004206120A patent/AU2004206120B2/en not_active Ceased
- 2004-01-20 SI SI200431983T patent/SI1592384T1/sl unknown
- 2004-01-20 NZ NZ569331A patent/NZ569331A/xx not_active IP Right Cessation
- 2004-01-20 US US10/543,764 patent/US8008258B2/en not_active Expired - Fee Related
- 2004-01-20 DK DK04703462.4T patent/DK1592384T3/da active
- 2004-01-20 WO PCT/IL2004/000054 patent/WO2004064717A2/en active Application Filing
- 2004-01-20 CA CA2513567A patent/CA2513567C/en not_active Expired - Fee Related
-
2005
- 2005-08-18 NO NO20053860A patent/NO333579B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MXPA05007711A (es) | 2005-09-30 |
US20060264354A1 (en) | 2006-11-23 |
NO333579B1 (no) | 2013-07-15 |
NO20053860D0 (no) | 2005-08-18 |
CA2513567C (en) | 2012-10-23 |
SI1592384T1 (sl) | 2013-03-29 |
AU2004206120A1 (en) | 2004-08-05 |
AU2004206120B2 (en) | 2009-09-24 |
RU2339397C2 (ru) | 2008-11-27 |
WO2004064717A2 (en) | 2004-08-05 |
DK1592384T3 (da) | 2012-12-17 |
ZA200505733B (en) | 2006-10-25 |
EP1592384A2 (en) | 2005-11-09 |
PT1592384E (pt) | 2013-01-28 |
EP1592384A4 (en) | 2008-12-31 |
NO20053860L (no) | 2005-10-20 |
WO2004064717A3 (en) | 2005-10-13 |
CA2513567A1 (en) | 2004-08-05 |
US8008258B2 (en) | 2011-08-30 |
NZ569331A (en) | 2010-08-27 |
ES2397836T3 (es) | 2013-03-11 |
EP1592384B1 (en) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005126412A (ru) | Сор1 для лечения воспалительных заболеваний кишечника | |
JP2017057230A5 (ru) | ||
EA200301165A1 (ru) | Лекарственное средство на основе оксикодона | |
JP2013507439A5 (ru) | ||
JP2009500045A5 (ru) | ||
CA2594215A1 (en) | Sustained-release nanoparticle compositions and methods for using the same | |
JP2010522242A5 (ru) | ||
HUP0301444A3 (en) | The use of ribavirin-pegylated interferon alfa for the preparation of pharmaceutical compositions for the treatment of hcv infection | |
RU2004135563A (ru) | Лекарственное средство для лечения повышенной активности мочевого пузыря | |
WO2002088100A3 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
JP2002528502A5 (ru) | ||
RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
RU2004138807A (ru) | Новые сложные эфиры этоногестрела | |
RU2010153688A (ru) | Режим дозирования телапревира | |
RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
CA2389032A1 (en) | Preventive or therapeutic agents for inflammatory diseases of intestine | |
WO2002102743A3 (de) | Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel | |
RU2006115784A (ru) | Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта | |
RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
JP2003514025A5 (ru) | ||
RU2006113366A (ru) | Терапевтическое лечение | |
MXPA04003506A (es) | Metodo para la preparacion de una composicion farmaceutica que comprende acido 5-aminosalicilico para el uso en el tratamiento de la colitis ulcerativa y de la enfermedad de crohn. | |
JP2003246730A5 (ru) | ||
CA2469702A1 (en) | Darifenacin for use in the treatment of urgency induced by overactive bladder | |
RU2005131943A (ru) | Лечебные и/или профилактические средства для хронических болезней кожи |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20190121 |